scholarly journals Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening

2020 ◽  
Vol 3 (5) ◽  
pp. 1008-1016
Author(s):  
Wei Zhu ◽  
Miao Xu ◽  
Catherine Z. Chen ◽  
Hui Guo ◽  
Min Shen ◽  
...  
Author(s):  
Tsukasa Hasegawa ◽  
Riyo M. Imamura ◽  
Tateki Suzuki ◽  
Takao Hashiguchi ◽  
Takao Nomura ◽  
...  

2007 ◽  
Vol 69 (4) ◽  
pp. 269-279 ◽  
Author(s):  
Dariusz Plewczynski ◽  
Marcin Hoffmann ◽  
Marcin von Grotthuss ◽  
Krzysztof Ginalski ◽  
Leszek Rychewski

2003 ◽  
Vol 107 (2) ◽  
pp. 245-255 ◽  
Author(s):  
Yevgeny Berdichevsky ◽  
Romy Zemel ◽  
Larisa Bachmatov ◽  
Alex Abramovich ◽  
Ruth Koren ◽  
...  

Author(s):  
Chunlong Ma ◽  
Michael Dominic Sacco ◽  
Zilei Xia ◽  
George Lambrinidis ◽  
Julia Alma Townsend ◽  
...  

Author(s):  
Wei Zhu ◽  
Miao Xu ◽  
Catherine Z. Chen ◽  
Hui Guo ◽  
Min Shen ◽  
...  

AbstractThe outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. The 3C like protease (3CLpro), or main protease (Mpro) of SARS-CoV-2 is a valid drug target as it is a specific viral enzyme and plays an essential role in viral replication. We performed a quantitative high throughput screening (qHTS) of 10,755 compounds consisting of approved and investigational drugs, and bioactive compounds using a SARS-CoV-2 3CLpro assay. Twenty-three small molecule inhibitors of SARS-CoV-2 3CLpro have been identified with IC50s ranging from 0.26 to 28.85 μM. Walrycin B (IC50 = 0.26 µM), Hydroxocobalamin (IC50 = 3.29 µM), Suramin sodium (IC50 = 6.5 µM), Z-DEVD-FMK (IC50 = 6.81 µM), LLL-12 (IC50 = 9.84 µM), and Z-FA-FMK (IC50 = 11.39 µM) are the most potent 3CLpro inhibitors. The activities of anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds using a SARS-CoV-2 cytopathic effect assay. The results demonstrated a set of SARS-CoV-2 3CLpro inhibitors that may have potential for further clinical evaluation as part of drug combination therapies to treating COVID-19 patients, and as starting points for chemistry optimization for new drug development.


Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
L Hingorani ◽  
NP Seeram ◽  
B Ebersole

Planta Medica ◽  
2015 ◽  
Vol 81 (16) ◽  
Author(s):  
K Georgousaki ◽  
N DePedro ◽  
AM Chinchilla ◽  
N Aliagiannis ◽  
F Vicente ◽  
...  

Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
LS Espindola ◽  
RG Dusi ◽  
KR Gustafson ◽  
J McMahon ◽  
JA Beutler

2014 ◽  
Author(s):  
Clair Cochrane ◽  
Halil Ruso ◽  
Anthony Hope ◽  
Rosemary G Clarke ◽  
Christopher Barratt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document